Trial Profile

A pivotal study of fulvestrant in Breast cancer.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary)
Indications Breast cancer
Focus Adverse reactions

Most Recent Events

09 Dec 2019 According to a Eagle Pharmaceuticals media release, the company expects to initiate this trial in 2020.
12 Aug 2019 New trial record
08 Aug 2019 According to a Eagle Pharmaceuticals media release, this pivotal trial is expected to be completed within approximately 12 months of commencing enrollment

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com